Those results showed that the TCR diversity and clonality of PD-1+ CD8+ T cells in peripheral blood may be promising predictors of response to anti-PD-1/PD-L1 therapy and survival outcomes in NSCLC patients (108). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.